Bayer
100 Bayer Boulevard
Whippany
New Jersey
07981
United States
755 articles with Bayer
-
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
-
Bayer Focuses on Farmers and Drives Innovation into 2022
11/11/2021
Harvest is a time for North American farmers to reflect on the past season’s successes and challenges, while looking ahead to what’s next.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
-
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA® (finerenone)
10/27/2021
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA ® (finerenone)
-
Bayer fuels leading market positions in Crop Science through delivery of unmatched innovation
10/19/2021
Bayer today announced continued progress in delivering customer-focused, sustainable agricultural innovation in an update with investors.
-
Ensoma Taps Gene Therapy Leader as First CEO
10/11/2021
After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO. -
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look. -
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Biogen and Samsung Bioepis Heat Up the Lucrative AMD Market with First Biosimilar Approval
9/20/2021
Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market. -
Latest Analyses of Vitrakvi® (larotrectinib) Support Consistently Meaningful Clinical Profile for Both Adult and Pediatric Patients with TRK Fusion Cancer
9/16/2021
Data from three subset analyses and one matching-adjusted indirect comparison model for Vitrakvi® showcase its consistent noteworthy clinical profile and add to its existing safety data for patients with solid tumors harboring an NTRK gene fusion.
-
Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards
9/10/2021
Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards
-
Bayer to Highlight Expanded Research from Growing Oncology Portfolio at ESMO Congress 2021
9/9/2021
Bayer will present new investigational data from its established portfolio of approved oncology therapies at the upcoming ESMO Congress 2021 from September 16-21, 2021.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes
8/28/2021
FIGARO-DKD is the first contemporary cardiorenal outcomes trial with the majority of patients who had an eGFR ≥60 ml/min/1.73m2 to show cardiovascular benefit in chronic kidney disease associated with type 2 diabetes; patients were included in this study if they had UACR levels 30–5000 mg/g
-
Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company's Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions
8/23/2021
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, announced it has achieved a milestone in its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products.
-
Berkeley Lights and Bayer announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits
8/11/2021
Berkeley Lights, Inc. a leader in the functional characterization of live biology, announced a multi-year agreement with Bayer to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits.
-
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
-
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...